Science backed, not borrowed

The global vitamin and dietary supplement market relies on clinical evidence in order to differentiate products in the marketplace. It's critical for manufacturers to formulate with ingredients that have clinical evidence to substantiate health benefits.

why floraglo® lutein?

FloraGLO® lutein’s efficacy is unparalleled, compared with other lutein brands — and demonstrated in human clinical trials time and time again — which is why so many manufacturers choose it.

100 human clinical trials
areds2

Have a question?

25 glorious years

25 glorious reasons

These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

The information on this webpage is a business-to-business information and not intended for the final consumer. Certain statements may not be applicable in all geographical regions. Product labeling and associated claims differs based upon government requirements and country or region specific information should also be considered when labeling or advertising to final consumers.

This web page and its associated brochures and other documents do not constitute or provide scientific or medical advice, diagnosis, or treatment and are distributed without warranty of any kind, either expressly or implied. This web page, its title or contents and associated brochures and other documents do not in any way make recommendations for health or marketing claims by the reader. Country and region specific regulations should be considered in this regard. Each claim or statement about the effectiveness of Kemin products and/or each claim or statement comparing the effectiveness of Kemin products to the effectiveness of other products is expressly limited to the United States, unless otherwise disclosed on the Kemin websites.

References: 

The Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni J & et al. Lutein/zeaxanthin for the treatment of age-related cataract: Areds2 randomized trial report no. 4. JAMA Ophthalmol. 131, 843–850 (2013)